DOUBLEDAY RICHARD 4
4 · DEXCOM INC · Filed Mar 24, 2021
Insider Transaction Report
Form 4
DEXCOM INCDXCM
DOUBLEDAY RICHARD
VP of Sales
Transactions
- Sale
Common Stock
2021-03-23$352.88/sh−18$6,352→ 7,745 total(indirect: By Trust) - Sale
Common Stock
2021-03-23$362.45/sh−94$34,070→ 6,654 total(indirect: By Trust) - Sale
Common Stock
2021-03-23$360.33/sh−655$236,018→ 7,016 total(indirect: By Trust) - Sale
Common Stock
2021-03-23$358.13/sh−74$26,502→ 7,671 total(indirect: By Trust) - Sale
Common Stock
2021-03-23$361.37/sh−268$96,847→ 6,748 total(indirect: By Trust)
Holdings
- 21,554
Common Stock
Footnotes (4)
- [F1]On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.
- [F2]Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.
- [F3]This transaction was executed in multiple trades at prices ranging from $359.70 to $360.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F4]This transaction was executed in multiple trades at prices ranging from $360.94 to $361.83. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.